[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340663-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340663-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immune-checkpoints-and-ncrnas-pioneering-immunotherapy-approaches-for-hematological-malignancies","Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies","","Hematological malignancies are typically treated with chemotherapy and radiotherapy as first-line conventional therapies, but non-coding RNAs (ncRNAs) have emerged as a rapidly expanding field influencing tumor growth, differentiation, and proliferation through targeting immunological checkpoints. This review summarizes studies from 2012 to 2024 linking immune checkpoints and ncRNAs with immunotherapy outcomes. It highlights latest immunotherapy advances, the role of immune checkpoints in immune homeostasis, and how dysregulation contributes to leukemia and lymphoma. It also addresses obstacles and future directions for fully harnessing immune checkpoint and ncRNA potential.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immune-checkpoints-and-ncrnas-pioneering-immunotherapy-approaches-for-hematological-malignancies/340663/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immune-checkpoints-and-ncrnas-pioneering-immunotherapy-approaches-for-hematological-malignancies/340663.png","ImageObject",300,407,{"name":42,"@type":43},"Theodora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why are immune checkpoints important in hematological malignancies?","Question",{"text":63,"@type":64},"Immune checkpoint inhibitors target molecules such as PD-1 and CTLA-4 that regulate T-cell responses. Cancer cells can evade immune surveillance by activating these checkpoints, and their dysregulation can contribute to leukemia and lymphoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do non-coding RNAs (ncRNAs) relate to immunotherapy in these cancers?",{"text":68,"@type":64},"ncRNAs influence tumor development and also intersect with immune checkpoints by modulating immune responses. They can regulate mechanisms underlying drug resistance and affect interactions between immune cells and cancer stem cells in the tumor microenvironment.",{"name":70,"@type":61,"acceptedAnswer":71},"What does the review cover regarding time range and research focus?",{"text":72,"@type":64},"The review summarizes studies from 2012 to 2024 examining immune checkpoints and ncRNAs in relation to hematological malignancies treated with immunotherapy. It focuses on recent advances, the immune homeostasis role of checkpoints, and future directions.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340663,1790523014,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":99,"preview_page_count":33,"preview_urls":145},687197207919,"https://ap-avatar.wpscdn.com/avatar/a000253d6f5f7c60be?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779446848396160552","Anvari et al. Cancer Cell International (2024) 24:410  \n[https://doi.org/10.1186/s12935-024-03596-8](https://doi.org/10.1186/s12935-024-03596-8)  \nCancer Cell International  \n REVIEW Open Access  \nImmune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies  \nSamira Anvari1, Mohsen Nikbakht2, Mohammad Vaezi3, Sedigheh Amini‑Kafiabad1* and Mohammad Ahmadvand4*  \nAbstract  \nHematological malignancies are typically treated with chemotherapy and radiotherapy as the first‑line conventional therapies. However, non‑coding RNAs (ncRNAs) are a rapidly expanding field of study in cancer biology that influ‑ ences the growth, differentiation, and proliferation of tumors by targeting immunological checkpoints. This study reviews the results of studies (from 2012 to 2024) that consider the immune checkpoints and ncRNAs in relation to hematological malignancies receiving immunotherapy. This article provides a summary of the latest advancementsin immunotherapy for treating hematological malignancies, focusing on the role of immune checkpoints and ncRNAsin the immune response and their capacity for innovative strategies. The paper also discusses the function of immune checkpoints in maintaining immune homeostasis and how their dysregulation can contribute to developing leuke‑ mia and lymphoma. Finally, this research concludes with a discussion on the obstacles and future directions in this rapidly evolving field, emphasizing the need for continued research to fully harness the capacity of immune check‑ points and ncRNAs in immunotherapy for hematological malignancies.  \nKeywords miRNA, lncRNA, Leukemia, Immune checkpoints, Immunotherapy  \n*Correspondence: Sedigheh Amini‑Kafiabad [dr.amini@gmail.com](dr.amini@gmail.com)[ ](dr.amini@gmail.com)Mohammad Ahmadvand  \n[Ahmadvand.mohamad64@yahoo.com](Ahmadvand.mohamad64@yahoo.com)  \n1 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, Iran  \n2 Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran  \n3 Hematology, Oncology, and Stem Cell Transplantation Research Center Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran  \n4 Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Research Institute for Oncology, Hematology and Cell Therapy, Tehran University of Medical Sciences, Tehran, Iran  \nIntroduction  \nAnti-programmed death-1 (PD-1) and anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) immune checkpoint inhibition have drastically changed the solid tumor cancer therapy landscape [1, 2]. However, their efficacy in hematological malignancies has been less pronounced. It is recognized that cancerous cells can circumvent immune surveillance by activating immune checkpoints, which serve as inhibitors of the immune system. Immune checkpoint inhibitors (ICIs) have revolutionized solid tumor treatment by reactivating the anti-tumor effect mediated by T-lymphocytes [3–5]. A number of T cell immune checkpoint molecules, such as CTLA-4 and PD-1, have been shown to be viable targets for therapy because of their non-redundant control over T cell responses in malignancies that are hematological in nature [6]. Hematological malignancies have responded  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution‑NonCommercial‑NoDerivatives 4.0 International License, which permits any non‑commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are inc","cbCaibI6SsFHj3sS","https://ap.wps.com/l/cbCaibI6SsFHj3sS","pdf",1790123,24,"English","# Abstract\n# Introduction\n## Immune checkpoint blockade in hematological malignancies\n## Roles of non-coding RNAs (ncRNAs)\n## ncRNAs as therapeutic targets and biomarkers\n## Immunotherapy resistance and tumor microenvironment","[{\"question\":\"Why are immune checkpoints important in hematological malignancies?\",\"answer\":\"Immune checkpoint inhibitors target molecules such as PD-1 and CTLA-4 that regulate T-cell responses. Cancer cells can evade immune surveillance by activating these checkpoints, and their dysregulation can contribute to leukemia and lymphoma.\"},{\"question\":\"How do non-coding RNAs (ncRNAs) relate to immunotherapy in these cancers?\",\"answer\":\"ncRNAs influence tumor development and also intersect with immune checkpoints by modulating immune responses. They can regulate mechanisms underlying drug resistance and affect interactions between immune cells and cancer stem cells in the tumor microenvironment.\"},{\"question\":\"What does the review cover regarding time range and research focus?\",\"answer\":\"The review summarizes studies from 2012 to 2024 examining immune checkpoints and ncRNAs in relation to hematological malignancies treated with immunotherapy. It focuses on recent advances, the immune homeostasis role of checkpoints, and future directions.\"}]","Immune checkpoints and ncRNAs: pioneering immunotherapy approaches for hematological malignancies | PDF",1790038000,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a0d7a6ffeb138dc900fcb7880f944bbf.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c231cbc4fa898853e839ea4648589ee8.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/046b7f339e891df4dc1b71559c3ddb5f.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/445d8d17b06f9fffec882fe8c147b0ec.webp",980,1301]